Probucol, 4,4-(isopropylidenedithio)bis(2,6-di-tert-butyl-
70#{176}C freezer)
and thawing (37#{176}C water bath). The freeze-thawed cell lysates were filter-sterilized and stored at -70#{176}C until assayed.
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RESULTS
Zymosan-primed mice responded to the subsequent intravenous injection of LPS (100 tg) with a fall in serum zinc level and a rise in serum triglyceride levels but no change in serum cholesterol level ( Table  1 ). The rise in serum triglycerides did not occur in mice that had not received the priming dose of zymosan, although the zinc response was present (Table  1) . Previous studies suggest that the fall in serum zinc is due to release of IL 1 or some other cytokine (21). Furthermore, the increase in serum triglycerides can be attributed to the release of TNF (22). Therefore, although the evidence is indirect, these in vivo data suggest that LPS induces release of both IL 1 and TNF in zymosan-primed mice. Using the in vivo system, the effect of probucol on these serum components was examined. Two weeks of oral dosing with probucol at 100 mg/(kg. day), from the time of intravenous injection of zymosan to the time of challenge, inhibited the LPS-induced fall in serum zinc level but did not affect the LPS-induced increase in triglycerides and had no effect on total cholesterol levels ( Table  2) . With this dosage regimen, probucol administration to mice that had received zymosan but not LPS had no effect on these parameters (Table 2 ). The indirect evidence mentioned above suggested that probucol was able to inhibit LPS-induced secretion of IL 1 but not of TNF. To obtain direct evidence, peritoneal or splenic macrophages were collected from vehicle-dosed mice (water, by gavage) or probucoldosed mice (100 mg/kg, by gavage 40, 24, and 16 h before the removal of macrophages) or mice fed control or 0.25% probucol diet for 2 wk and stimulated in vitro with LPS (100 sg/ml).
As shown in Table 3 , probucol administration produced a significant inhibition of IL 1 secretion.
This result could also be explained by probucol-induced synthesis of an inhibitor of the biological activity of IL 1 in the bioassays.
This possibility can be discounted, however, because mixing supernatants from LPS-stimulated cultures of macrophages from probucol-dosed mice did not inhibit the activity of ETAF, a crude source of IL 1 ( Table 3 ). The effect of dietary probucol (0.25% for 2 wk) on ex vivo LPSinduced IL 1 release was also determined with a specific binding assay for 1251-labeled IL 1. As shown in Table  3 , probucol administration produced a significant (P < 0.05) inhibition of IL 1 release. The release of TNF was also measured, but no inhibition by probucol was observed (Table  4) , a result consistent with the in vivo data described above. In none of the studies in which macrophages were collected from probucol-dosed mice was the yield of cells per mouse, the morphology of the cells, or the percent adherence to tissue culture dishes altered by the treatment. When LPS-stimulated macrophages were fixed and used to stimulate thymocytes, there was no change in the level of membrane-bound IL 1 between the vehicleand probucol-treated groups (Table 4) , which suggests that probucol preferentially reduced the level of extracellular IL 1. Furthermore, levels of Con A-induced release of IL 2 and IL 3 by a mixed spleen cell population were similar in vehicleand probucol-treated groups, which suggests that helper T lymphocyte function was not affected by probucol. 124.6 ± 116.4 ± 5.1 6.2 "Mice were injected iv. with 2 mg zymosan in 0.5 ml saline, or with 0.5 ml saline, 2 weeks prior to LPS administration.
Serum samples were collected 6 h after the injection of LPS. Values represent mean ± SEM.
< 0.01 compared with the zymosan-primed saline control group. 'P < 0.01 compared with the nonprimed saline control group. Normal 6-week CD-I mice were given zymosan at 2 mg/0.5 ml saline per mouse iv. mg/kg by gavage, once per day for 14 days. The day after the last dose, mice were injected Serum samples were collected 6 h later.
bMean ± SEM (n). 
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The FASEB journal Table  6) . Probucol had no effect on any of these parameters in nonarthritic rats. The absence of an effect on cholesterol in the nonarthritic animals is surprising but may be related to the unusually low cholesterol levels seen in the vehicle-treated nonarthritic group (Table 6 ). 
